Skip to main content

Genmab Plans to Delist from Neuer Markt

SAN FRANCISCO, Aug. 7 - Copenhagen, Denmark-based Genmab will no longer trade on Germany's Neuer Markt of the Frankfurt Stock Exchange as of the close of the market on August 16, the company said today.

 

Genmab, developer of fully-human antibodies, will continue to be listed on the Copenhagen Stock Exchange.

 

More than 95 percent of the company's stock is traded on the Copenhagen Stock Exchange, and delisting from the Neuer Markt will eliminate costs associated with double listing, Genmab CEO Lisa Drakeman said in a statement.

 

Click here for more information.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.